DE3856297T2 - Amorphe Form von Aztreonam - Google Patents

Amorphe Form von Aztreonam

Info

Publication number
DE3856297T2
DE3856297T2 DE3856297T DE3856297T DE3856297T2 DE 3856297 T2 DE3856297 T2 DE 3856297T2 DE 3856297 T DE3856297 T DE 3856297T DE 3856297 T DE3856297 T DE 3856297T DE 3856297 T2 DE3856297 T2 DE 3856297T2
Authority
DE
Germany
Prior art keywords
amorphous form
aztreonam
methylethoxy
ami
imino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3856297T
Other languages
English (en)
Other versions
DE3856297D1 (de
Inventor
Sailesh Amilal Varia
George Eugene Reier
James Douglas Pipkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of DE3856297D1 publication Critical patent/DE3856297D1/de
Publication of DE3856297T2 publication Critical patent/DE3856297T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE3856297T 1987-07-01 1988-06-30 Amorphe Form von Aztreonam Expired - Fee Related DE3856297T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6839287A 1987-07-01 1987-07-01

Publications (2)

Publication Number Publication Date
DE3856297D1 DE3856297D1 (de) 1999-03-04
DE3856297T2 true DE3856297T2 (de) 1999-06-02

Family

ID=22082279

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3856297T Expired - Fee Related DE3856297T2 (de) 1987-07-01 1988-06-30 Amorphe Form von Aztreonam

Country Status (9)

Country Link
EP (1) EP0297580B1 (de)
JP (1) JP2701869B2 (de)
KR (1) KR890002141A (de)
CN (1) CN1028234C (de)
AT (1) ATE175965T1 (de)
CA (1) CA1339136C (de)
DE (1) DE3856297T2 (de)
ES (1) ES2127178T3 (de)
GR (1) GR3029873T3 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191492B (de) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
ES2406405T3 (es) 2000-12-27 2013-06-06 Gilead Sciences, Inc. Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares
US7145017B2 (en) 2002-08-05 2006-12-05 TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság Preparation of Aztreonam
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
US7262293B2 (en) 2003-07-02 2007-08-28 Corus Pharma Aztreonam L-lysine and methods for the preparation thereof
CA2543650C (en) 2003-12-25 2010-10-26 Eisai Co., Ltd. A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
JP2008505189A (ja) 2005-05-09 2008-02-21 シコール インコーポレイティド アズトレオナムの製造方法
CN101233111A (zh) * 2005-06-23 2008-07-30 卫材R&D管理有限公司 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
ES2556173T3 (es) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (de) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101579336B (zh) * 2009-07-07 2010-06-23 重庆市庆余堂制药有限公司 一种注射用氨曲南及其生产方法
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN101912356B (zh) * 2010-08-02 2012-01-11 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1181075A (en) * 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile

Also Published As

Publication number Publication date
CA1339136C (en) 1997-07-29
ES2127178T3 (es) 1999-04-16
ATE175965T1 (de) 1999-02-15
EP0297580B1 (de) 1999-01-20
KR890002141A (ko) 1989-04-08
JPS6422874A (en) 1989-01-25
GR3029873T3 (en) 1999-07-30
CN1028234C (zh) 1995-04-19
CN1030238A (zh) 1989-01-11
EP0297580A1 (de) 1989-01-04
JP2701869B2 (ja) 1998-01-21
DE3856297D1 (de) 1999-03-04

Similar Documents

Publication Publication Date Title
ATE175965T1 (de) Amorphe form von aztreonam
FI914928A (fi) Hydroximetyl (metylencyklopentyl) puriner och -pyrimidiner.
FI921087A0 (fi) Nya estrar av tienylkarboxylsyror och aminoalkoholer, deras kvaterniseringsprodukter och framstaellning och anvaendning av naemnda foereningar.
CA2418125A1 (en) Beta-lactams useful in the preparation of substituted isoserine esters
AU557096B2 (en) Thiazole derivatives
ES2126636T3 (es) Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
AU8293387A (en) Quinoline compound
FI852806L (fi) 2-substituerade -1,3-propylidendifosfonatderivat och deras framstaellning.
SE8600017D0 (sv) New compound
DE69017174T2 (de) Substituierte Oxophtalazinyl-Essigsäuren und deren Analogen.
ES2051711T3 (es) Procedimiento para preparar 2-oxo-1-(((sulfonil sustituido)amino)-carbonil)-azetidinas.
DK297485D0 (da) Carbapenemer med kvaternaere heteroarylalkylthio 2-substituenter samt laegemiddel indeholdende saadanne forbindelser
SE8705068D0 (sv) Kristallina salter av /3s(z)/-2-///1-(2-amino-4-tiazolyl)-2-//2,2-dimetyl-4-oxo-1-(sulfooxi)-3-azetidinyl/-amino/-2-oxoetyliden/-amino/oxi/ettiksyra
FI891866A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten sulfonanilidien valmistamiseksi
DE69029069D1 (de) Verwendung von Xanthinderivaten gegen Magengeschwüre
IT1190660B (it) Composto ad attivita' mucoregolatrice e antitosse,procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1190661B (it) Composto ad attivita' mucoregolatrice e fluidificante,procedimento per la sua preparazione e relative composizioni farmaceutiche

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee